Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.

Shubha Bhat Maitri PatelKristine DulyDavid K Choi

Published in: The Annals of pharmacotherapy (2022)

As an interchangeable biosimilar with comparable efficacy and safety to reference adalimumab, adalimumab-adbm is an important advance toward cost-effective management of inflammatory diseases.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
hidradenitis suppurativa
ulcerative colitis
oxidative stress
disease activity
systemic lupus erythematosus